ClinConnect ClinConnect Logo
Search / Trial NCT05591066

The Patient and Family Centered I-PASS LISTEN Study: Language, Inclusion, Safety, and Teamwork for Equity Now

Launched by BOSTON CHILDREN'S HOSPITAL · Oct 19, 2022

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Family Centered Rounds Patient Safety Errors Limited English Proficiency Health Disparities Adverse Events Patient Experience Family Engagement Interprofessional Communication Language Barriers

ClinConnect Summary

The Patient and Family Centered I-PASS LISTEN Study is looking to improve how medical teams communicate with patients and their families in hospitals, especially for those who speak languages other than English. Originally developed in 2014, the PFC I-PASS program changed how doctors and nurses talk to patients during their daily check-ups, making conversations more inclusive and easier to understand. This new study, called PFC I-PASS+, builds on that program by adding interpreters and training for healthcare providers on better communication and understanding different cultures. The goal is to see if this new approach can help improve the hospital experience and safety for patients.

To participate in the study, patients admitted to pediatric units at certain hospitals can join, especially if they are 13 years or older with permission from a parent or guardian. Parents or caregivers of patients, nurses, doctors in training, and hospital leaders are also eligible to take part. Participants can expect to be involved in discussions about their care and will receive support in their preferred language. This study aims to ensure that everyone involved in a patient's care feels included and understood, no matter what language they speak.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • All patients admitted to the pediatric inpatient study units of participating hospitals
  • Patients themselves who are age 13 and up (if they provide assent and their parent or guardian gives permission)\*
  • Parents/caregivers of patients of all ages who speak English, Arabic, Armenian, Bengali, Chinese (Mandarin and Cantonese), Karen, Korean, Nepali, Quiche, Spanish, Somali, and Vietnamese (and/or other languages if resources allow)
  • Nurses working on these units
  • Residents working on these units
  • Medical and nursing students working on these units
  • Hospital leaders working at these hospitals
  • \*Note for Consenting: Patients (13-18yo) who are in state custody and assent for themselves to complete surveys but lack legal guardian/caregiver present to offer consent are not being approached to complete surveys. These patients may still be enrolled in the study but not consented to complete patient-facing forms.
  • Exclusion Criteria: None

About Boston Children's Hospital

Boston Children's Hospital is a leading pediatric healthcare institution renowned for its commitment to advancing child health through innovative research and exceptional clinical care. As a prominent clinical trial sponsor, the hospital leverages its extensive expertise in pediatric medicine to conduct rigorous and ethically sound research studies aimed at improving treatment options and outcomes for children. With a collaborative approach that integrates cutting-edge technology and multidisciplinary teams, Boston Children's Hospital is dedicated to translating scientific discoveries into practical applications that enhance the well-being of young patients and their families.

Locations

Birmingham, Alabama, United States

Los Angeles, California, United States

Birmingham, Alabama, United States

Omaha, Nebraska, United States

Bronx, New York, United States

Pittsburgh, Pennsylvania, United States

Amarillo, Texas, United States

Oakland, California, United States

Columbus, Ohio, United States

Patients applied

0 patients applied

Trial Officials

Alisa Khan, MD, MPH

Principal Investigator

Boston Children's Hospital/Harvard Medical School

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials